Table 3.
FN Risk Category Results
| ITT Population | FN Risk Category | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1/2 | 3/4 | ||||||
| Trilaciclib | Placebo | Trilaciclib | Placebo | Trilaciclib | Placebo | Trilaciclib | Placebo | |
| Mean DSN in cycle 1, days (SD) | 0 (1.8) | 4 (5.1) | 0 (1.2) | 2 (3.8) | 1 (2.1) | 5 (5.1) | 0 (0.8) | 9 (7.5) |
| Patients with SN, n (%) | 14 (11.4) | 63 (52.9) | 2 (6.3) | 11 (31.4) | 11 (12.9) | 46 (59.7) | 1 (16.7) | 6 (85.7) |
Abbreviations: DSN, duration of severe (grade 4) neutropenia; FN, febrile neutropenia; ITT, intention-to-treat; SD, standard deviation; SN, severe (grade 4) neutropenia.